DUBLIN–(BUSINESS WIRE)–The “Investigation Report on China’s Rituximab Market, 2020-2024” report has been added to ResearchAndMarkets.com’s offering.
The global sales of rituximab have been very mature. In the year 2019, Rituximab recorded a revenue of US$6.7 billion. The drug was mostly used for tumor treatment.
Rituximab (Roche’s trade name: MabThera/Rituxan) is a human-mouse chimeric anti-CD20 monoclonal antibody that was approved for the treatment of tumors in 1997. With the deep understanding of B cells and their mechanisms of action, the therapeutic range of Rituximab has expanded from B-cell malignancies to autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, etc. In Sep 2019, FDA approved Roche’s rituximab in combination with glucocorticoids for treating granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) disorders.
In China, Roche’s Rituximab is mainly used to treat non-Hodgkin lymphoma. As a major malignant lymphoma, non-Hodgkin lymphoma takes up a much larger proportion of malignant lymphoma than Hodgkin’s disease in China. The incidence of non-Hodgkin’s lymphoma has risen rapidly from 20 cases per 1 million people at the end of the 20th century to 60 cases per 1 million people in 2019.
On December 10, 2019, Roche announced that its Rituxan/MabThera, (rituximab) has been formally approved by the National Medical Products Administration (NMPA) of China for the initial treatment of follicles Monotherapy for patients with lymphoma (FL) who have achieved complete or partial remission after rituximab combined with chemotherapy, and combined treatment with fludarabine and cyclophosphamide (FC) for previously untreated or relapsed/refractory patients with chronic lymphocytic leukemia (CLL).
According to this market research, in 2019, the sales value of Rituximab reached CNY1.42 billion(US$206 million) in China. By the end of 2018, there has been no China-made Rituximab on the market, and the market is monopolized by the products of Roche and its subsidiary Genentech.
However, starting in 2019, Shanghai Henlius Biotech, Inc.’s rituximab (trade name: Hanlikang) began to be listed on the Chinese market. According to sales in 2019, Roche and Genentech’s rituximab products accounted for approximately 98% of the Chinese market, and the corporate market share was occupied by Shanghai Henlius Biotech, Inc.
According to the market research, it is expected that with the launch of more domestic rituximab products in China, the market share of Roche and Genentech will continue to decline in 2020-2024. But for a long period of time, Roche and Genentech will still occupy the major market share of rituximab in China.
Topics Covered:
Key Topics Covered:
1 Basic Concept of Rituximab
1.1 Indications for Rituximab
1.2 Development History of Rituximab in China
1.3 Governmental Approval of Rituximab in China
2 Sales of Rituximab in China, 2015-2019
2.1 Sales Value of Rituximab in China 2015-2019
2.1.1 Overall Sales Value of Rituximab in China 2015-2019
2.1.2 Sales Value of Rituximab in Different Regions of China
2.2 Sales Volume of Rituximab
2.2.1 Overall Sales Volume of Rituximab in China 2015-2019
2.2.2 Sales Volume of Rituximab in Different Regions of China
2.3 Sales of Rituximab by Dosage Form in China
3 Major Rituximab Manufacturers in China, 2015-2019
3.1 Market Share of Major Rituximab Manufacturers in China
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Roche
3.2.1 Enterprise Profile
3.2.2 Sales of Roche’s Rituximab in China
3.3 Genentech
3.3.1 Enterprise Profile
3.3.2 Sales of Genentech’s Rituximab in China
3.4 Shanghai Henlius Biotech, Inc.
3.4.1 Enterprise Profile
3.4.2 Sales of Genentech’s Rituximab in China
4 Prices of Rituximab in China, 2019-2020
4.1 Average Prices of Rituximab in China
4.1.1 Average Price of Rituximab in China
4.1.2 Average Price of Rituximab in Different Regions of China
4.2 Prices of Major Manufacturers’ Rituximab in China
4.2.1 Price of Roche’s Rituximab(Rituxan/MabThera) in China
4.2.2 Price of Genentech’s Rituximab(Rituxan) in China
4.2.3 Price of Shanghai Henlius Biotech, Inc.’s Rituximab(Hanlikang) in China
5 Prospects of Chinese Rituximab Market, 2020-2024
5.1 Factors Influencing Rituximab Development in China
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size of Rituximab in China 2020-2024
5.3 Forecast on Competition Pattern
For more information about this report visit https://www.researchandmarkets.com/r/d4vxcy
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
JAKARTA, INDONESIA - Media OutReach Newswire - 22 November 2024 - VinFast Auto has officially…
SYDNEY, AUSTRALIA - Media OutReach Newswire - 22 November 2024 - The global cryptocurrency market…
HANOI, VIETNAM – Media OutReach Newswire - 22 November 2024 - By capitalizing on its…
HANGZHOU, CHINA - Media OutReach Newswire - 22 November 2024 - As the 2024 World…
BEIJING, CHINA - Media OutReach Newswire - 22 November 2024 - The 2024 Beijing Changping…
Tickets Now Available via Urbtix HONG KONG SAR - Media OutReach Newswire - 22 November…
